Epigenetics is the structural changes in chromosomal regions, which signal or perpetuate alteration in gene expression by turning it on or off. Epigenetic alteration includes DNA methylation, histone modification, chromatin remodeling, genomic imprinting, X chromosome inactivation, and non-coding RNA regulation affecting gene transcription. Epigenetics is applied for the studies of oncology, developmental biology, drug development, and non-oncological disorders such as Alzheimer’s disease and respiratory disease. Epigenetics has applications in in forensic science for paternity testing, distinguishing between identical twins, identification of tissue origin, and for estimation of postmortem interval. Increasing application of epigenetics is expected to propel growth of the epigenetics market.

Epigenetics Market Drivers

Increasing research to study the epigenetics of the genome (study called epigenomics) is expected to boost growth of the epigenetics market over the forecast period. Genome-wide epigenetic studies play an important role in the diagnostics of human diseases. Moreover, implementation of epigenetics for oncology research is estimated to propel the growth of epigenetics market. For instance, Constellation Pharmaceuticals, in April 2018, invested US$ 100 million for development of cancer epigenetics platform and ongoing ProSTAR and ORIOn-E trials, which are designed to demonstrate the potential for CPI-1205 and CPI-0610, used for cancer therapy. Moreover, increasing whole genome sequencing projects such as Human Genome Project is resulting into increasing adoption of epigenetic-based products, which in turn is driving growth of the epigenetics market size.

Increasing government initiatives to enhance epigenetic research is fueling growth of the epigenetics market. For instance, in 2017, National Institutes of Health (NIH) planned to award 10 grants for supporting social epigenomics research in health disparities. The National Institute on Minority Health and Health Disparities (NIMHD), a part of the National Institutes of Health, committed US$ 26.2 million for nine awards over the term of five year. Moreover, in 2011, epigenetic related research was awarded US$ 11 million grant by the U.S. National Institute of Environmental Health Sciences. In same year, European Commission launched US$ 52.1 million project named BLUEPRINT, which aims to generate 100 reference epigenomes of healthy and leukaemic cells.

Furthermore, organic and inorganic growth strategies such as merger, collaboration, acquisition and product launches by market players of epigenetics market are expected to fuel growth of the epigenetics market. For instance, in 2012, Epizyme partnered with Summit, a subsidiary of Celgene to develop personalized therapeutics for patients with genetically defined cancers by inhibiting histone methyl transferases (HMTs), an important epigenetic target class. Under this agreement, Celgene will receive an exclusive license outside the U.S. to some of Epizyme’s programs for the period of three years and has the right to extend this option period for one year with additional funding. Moreover, In January 2016, Merck collaborated with the Cancer Research Technology in U.K., to develop inhibitors of protein arginine methyltransferase 5 (PRMT5).

Increasing incidence of cancer is also expected to upsurge epigenetics market in the near future. For instance, the global cancer prevalence was predicted to be 32.5 million in 2012, by Cancer Research UK, which is expected to increase by 68% by 2030. Furthermore, according to National Cancer Institute (NCI), people undiagnosed cancer patients reached nearly 14.5 million in 2014, and the number is expected to reach 19 million by 2024. Moreover, increasing prevalence of chronic disease is expected to boost growth of the epigenetics market. For instance, according to Center of Disease Control and Prevention (CDC), 2012, about half of the adult in U.S, which is 117 million, suffers from one or more chronic health conditions such as heart disease, stroke, cancer, type 2 diabetes, obesity, and arthritis

Epigenetics Market Restraint

High maintenance and cost of the instruments such as next generation sequencing or qPCR, implemented for epigenetic study are expected to be the key factors hindering growth of the epigenetics market.

Epigenetics Market - Regional Analysis

On the basis of geography, global epigenetics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America epigenetics market is expected to hold dominant position in the global market, owing to increasing funding for research and development activities by government. Furthermore, Asia Pacific epigenetics market is expected to be fastest growing region owing to high incidence of cancer. For instance, according to article in Japanese Journal of Clinical Oncology in 2012, more than 70% of total cancer mortality is reported in Asia Pacific region and it is projected to rise continuously to 16 million by 2025.

Epigenetics Market – Competitor

Epigenetics market is highly fragmented. Major players operating in market include Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Epigenetics Market Taxonomy

By Product

Consumables

Enzymes



Kits & Reagents

Instruments

By Application

Oncology

Developmental Biology

Drug Development

Metabolic diseases

Other

By End Users

Academic & Research Institutes

Pharmaceuticals & Biopharmaceutical Companies

Contract Research Organizations (CROs)

By Region: